Skip to main content
. Author manuscript; available in PMC: 2019 May 29.
Published in final edited form as: Clin Cancer Res. 2017 Jun 13;23(18):5639–5647. doi: 10.1158/1078-0432.CCR-17-1115

Figure 1.

Figure 1.

in vivo antitumor efficacy of glutaminase (BPTES) and transaminase (AOA) inhibitors in human pancreatic cancer xenografts. Mice with subcutaneously grown flank tumors (~150 mm3) were randomly assigned to two treatment arms and treated with vehicle or BPTES (12.5 mg/kg)/AOA (10 mg/kg), once daily intraperitoneal dose for 4 weeks. Tumor size was measured twice/week by using a digital caliper until the termination of experiments. A, Antitumor efficacy of BPTES in eight individual PDXs. B, Tumor growth curves of a representative xenograft (P198) treated with vehicle or BPTES, showing statistically significant tumor growth inhibition compared with vehicle treated mice. C, Antitumor efficacy of AOA in 13 PDXs. D, Tumor growth curves of representative xenograft (P253) treated with AOA showing statistically significant tumor growth inhibition compared with tumors of vehicle-treated mice. Data, mean ± SEM; n =7–10 tumors per group. **** P < 0.0001; **, P < 0.01; *, P < 0.05.